About CN Bio
CN Bio is a company based in Cambridge (United Kingdom) founded in 2009. CN Bio has raised $44.78 million across 14 funding rounds from investors including Gov.uk, Gates Foundation and CN Innovations. The company has 33 employees. CN Bio offers products and services including PhysioMimix OOC, Multi-chip plates, 3D validated cells, and DILI assay kit. CN Bio operates in a competitive market with competitors including Emulate, AxoSim, Mimetas, Obatala Sciences and Nortis, among others.
- Headquarter Cambridge, United Kingdom
- Employees 33
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website cn-bio.com
- Social LinkedIn X Facebook
- Legal Name Cn Bio Innovations Limited
- Date of Incorporation 28 Feb, 2008
- Jurisdiction THAME, OXFORDSHIRE
- Annual Revenue$2.64 M (USD)27as on Dec 31, 2022
- Net Profit-$5.1 M (USD)-37as on Dec 31, 2022
- Total Equity Funding$44.78M (USD)
in 14 rounds
- Latest Funding Round$21M (USD), Series B
Apr 2024
- InvestorsGov.uk
& 4 more
- Employee Count33
Products & Services of CN Bio
CN Bio offers a comprehensive portfolio of products and services, including PhysioMimix OOC, Multi-chip plates, 3D validated cells, and DILI assay kit.
Hardware for recreating human biology in drug testing
Plates used in organ-on-a-chip setups for research
Cells for modeling human tissues in experiments
Kit to predict drug-induced liver injury
Funding Insights of CN Bio
CN Bio has successfully raised a total of $44.78M across 14 strategic funding rounds. The most recent funding activity was a Series B round of $21 million completed in April 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $44.78M
- Total Rounds 14
- Last Round Series B — $21M
- First Round $555,016
(Jan 2010)
- Investors Count 5
Latest 10 of 14 funding rounds of CN Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2024 | $21M | Series B | – | – | |
| Mar 2021 | – | Grant | – | – | |
| Feb 2021 | – | Series A | – | – | – |
| Mar 2020 | $9M | Series A | – | CITIC | |
| Sep 2019 | – | Series A | – | – | – |
| Sep 2016 | – | Seed | – | – | – |
| Sep 2015 | – | Seed | – | – | – |
| Apr 2015 | – | Seed | – | – | – |
| Jul 2014 | – | Seed | – | – | – |
| Mar 2014 | $7.5M | Grant | – | – | – |
5 investors in total: 5 institutional.
Investors in CN Bio
CN Bio has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Gov.uk, Gates Foundation and CN Innovations.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | baylandcapital.tcc.mode | - | |
Online government services and information are provided to users. | 1707 | gov.uk | London, United Kingdom | |
Provides management consulting and business services to support organizational growth. | 2018 | citic.com | - | |
Conventional metal processing and precision stamping equipment are distributed. | 1935 | cn-innovations.com | Kowloon, China | |
Charitable foundation investments on poverty reduction and healthcare | 2000 | gatesfoundation.org | Seattle, United States |
Investor details for CN Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of CN Bio
19 people are tracked at CN Bio (8 in leadership, 11 in team); the tracked headcount is 33.
| Name | Role | Group |
|---|---|---|
David Hughes | CEO | Leadership |
Steven Lane | Finance Director | Leadership |
Paul Brooks | CEO | Leadership |
Deepak Singh | Vice President Global Sales & Marketing | Leadership |
Sarah Payne | Marketing Director | Leadership |
Tomasz Kostrzewski | Chief Scientific Officer | Leadership |
Adrian Rea | Director Of Sales & Business Development - EMEA & APAC | Leadership |
Neil Rumbelow | Director Engineering & Production | Leadership |
Daniel Carney | Lead Engineer | Team |
Emily Drea | General Counsel | Team |
Andrew Murray | Lead Software Engineer | Team |
Brian Mpofu | Finance Assistant | Team |
Emily Richardson | Lead Scientist | Team |
Gareth Guenigault | Lead Scientist - Services | Team |
Yassen Abbas | Lead Scientist | Team |
Rebecca Price | Office Manager | Team |
Ayisha Ahmed Malik | Content And Digital Marketing Manager | Team |
Dharaminder Singh | Lead Engineer - Consumables | Team |
Ovidiu Novac | Senior Scientist | Team |
Complete people profiles for CN Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of CN Bio
3 dated milestones of CN Bio across 15 years, from founding to its latest funding, stage changes and deals.
- Founded CN Bio is founded.
- Funding First funding round of $555K.
- Funding Latest funding round, Series B, of $21.0M.
Competitors of CN Bio
CN Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Emulate, AxoSim, Mimetas, Obatala Sciences and Nortis, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| emulatebio.com | 2013 | Boston, United States | $204.49M | 93 | Developer of in vitro models for drug development | |
| axosim.com | 2014 | New Orleans, United States | $6.78M | 27 | Nerve-on-a-chip technology is advanced by AxoSim for drug development improvement. | |
| mimetas.com | 2013 | Leiden, Netherlands | $28.9M | – | Microfluidics-based organ-on-a-chip models for drug evaluation are developed. | |
| obatalasciences.com | 2017 | New Orleans, United States | $3.54M | 10 | Provider of research enabling products and services to research centers | |
| nortisbio.com | 2007 | Woodinville, United States | $10.66M | 19 | Small human tissue segments are generated in microfluidic chips. | |
| netri.com | 2018 | Lyon, France | $8.89M | – | Microfluidic devices are developed for industrial applications and brain-on-a-chip models. | |
| mepsgen.com | 2019 | Seoul, South Korea | $29.26M | – | Developer of human organ model chips for pharmaceutical development | |
| hesperosinc.com | 2015 | Orlando, United States | – | 15 | Organ-on-a-chip solutions for preclinical testing are developed. | |
| tissuse.com | 2010 | Berlin, Germany | – | 31 | Multi-organ chip platform for tissue culture is developed. |
Detailed competitors of CN Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of CN Bio
The website of CN Bio (cn-bio.com) receives about 17K visits a month.
- Monthly visits17K
▲ 11% vs previous month
Websites whose visitors overlap most with CN Bio. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| cobrabio.com | 100% | – | – | View details | |
| selectscience.net | 88% | 117.5K | #363,624 | View details | |
genome.jp | genome.jp | 88% | – | #118,975 | – |
| onlymedics.com | 32% | 1.9K | #5,557,415 | View details | |
naiknaik.com | naiknaik.com | 26% | – | #1,974,693 | – |
Latest news on Cn Bio
Complete news archive for CN Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to CN Bio
10 companies that operate in the same segment as CN Bio (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about CN Bio
CN Bio was founded in 2009 and raised its 1st funding round 1 year after it was founded.
CN Bio is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
David Hughes is the current CEO of CN Bio.
CN Bio is a funded company, having raised a total of $44.78M across 14 funding rounds to date. The company's 1st funding round was a Grant of $7.5M, raised on Jan 2010.
CN Bio has 33 employees.
Annual revenue of CN Bio is $2.64M as on Dec 31, 2022.
CN Bio was founded in 2009 in Cambridge, United Kingdom, and operates in the biotechnology sector focused on in vitro modeling. Organ-on-a-chip platforms, including the PhysioMimix OOC benchtop device, are provided for studies in oncology, infectious diseases, metabolism, and inflammation. These systems support investigations into drug metabolism, toxicity, drug-drug interactions, therapeutic antibodies, proteins, and cellular therapies, with specific models for liver functions and barrier tissues.
CN Bio offers PhysioMimix OOC, Multi-chip plates, 3D validated cells, and DILI assay kit.
CN Bio has 5 investors. Key investors include Gov.uk, Gates Foundation, CN Innovations, CITIC Innovation Incubation Investment, and Bayland Capital.
CN Bio operates through Cn Bio Innovations Limited.